Loading...
•
Mar 31, 2022
West Pharma Q1 2022 Earnings Report
Reported a solid first quarter with net sales growth and reaffirmed full-year financial guidance.
Key Takeaways
West Pharmaceutical Services reported a strong first quarter in 2022, with net sales reaching $720.0 million, a 7.4% increase compared to the prior-year period. The company reaffirmed its full-year 2022 net sales guidance and raised its adjusted-diluted EPS guidance.
Net sales increased by 7.4% to $720.0 million, with organic sales growth of 11.0%.
Reported-diluted EPS rose by 15.1% to $2.29.
Adjusted-diluted EPS grew by 12.2% to $2.30.
Full-year 2022 net sales guidance reaffirmed, with adjusted-diluted EPS guidance raised to a new range of $9.30 to $9.45.
Revenue by Segment
Forward Guidance
The Company is reaffirming full-year 2022 net sales guidance to be in a range of $3.050 billion to $3.075 billion and is raising full-year 2022 adjusted-diluted EPS to be in a range of $9.30 to $9.45.
Positive Outlook
- Organic sales growth is expected to be in a range of 11% to 12%.
- Full-year adjusted-diluted EPS guidance range, based on current foreign currency exchange rates, includes an estimated headwind of $0.38.
- The revised guidance includes a $0.12 EPS positive impact from first-quarter tax benefits from stock-based compensation.
- For the remaining quarters of the year, our EPS guidance range assumes a tax rate of 23% and does not include potential tax benefits from stock-based compensation.
- Full-year 2022 capital spending is expected to be $380 million.
Challenges Ahead
- Net sales guidance, based on current foreign exchange rates, includes an estimated full-year 2022 headwind of $115 million.
- There is no certainty that actual results will be achieved in-line with current expectations.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...